close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by JCR Pharmaceuticals Co., Ltd.

News headline image
JCR Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
Italfarmaco and JCR Pharmaceuticals Announce Commercialisation Agreement for Givinostat in Japan and Strategic Collaboration in Rare Disease
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] Across Nine MENAT Markets
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by Ministry of Health, Labour and Welfare of Japan
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals Celebrates its 50th Anniversary of Advancing Science and Changing Lives
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals Presents Long-Term Clinical Data on Pabinafusp Alfa for the Treatment of Mucopolysaccharidosis Type II (MPS II) at ICIEM 2025
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
MEDIPAL HOLDINGS and JCR Pharmaceuticals Sign Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Therapy for GM2 Gangliosidosis
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals to Present at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) 2025
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals Selected for Japan’s Regenerative Medicine CDMO Subsidy Program
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic Medicines
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals Announces the Achievement of Enrollment in the JR-141 Global Phase III Clinical Trial
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by European Commission (EC)
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals Announces Launch of Mucopolysaccharidosis (MPS) Type II Disease Awareness Film Featured in The Next Frontier Series
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising CNS Uptake at American Society of Gene and Cell Therapy 28th Annual Meeting
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy 28th Annual Meeting
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by the U.S. FDA
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2025 Showcase Research from Its Investigational Treatments for Lysosomal Storage Disorders
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals to Present at the 21st Annual WORLDSymposium™ 2025
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals Initiates Phase III Clinical Trial of JR-142 in Japan, a Long-Acting Growth Hormone Therapy
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Announce Initiation of First Dosing in Phase I/II Clinical Trial of JR-446 for Mucopolysaccharidosis Type IIIB in Japan
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals Initiates First Dosing in Phase I Clinical Trial of JR-441 for Mucopolysaccharidosis Type IIIA
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals Presents Preclinical Gene Therapy Research at the European Society of Gene and Cell Therapy 31st Annual Congress
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals’ Data Presentations at SSIEM Annual Symposium 2024 Highlight Investigational Treatments for Lysosomal Storage Disorders
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
JCR Pharmaceuticals Announces Completion of Clinical Trial Notification Process in Japan for Phase I Study of JR-441 for Mucopolysaccharidosis Type IIIA
From JCR Pharmaceuticals Co., Ltd.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today